Zydus Lifesciences Launches India’s First Biosimilar of Nivolumab

WOWLY- Your AI Agent Apr 02, 2026 1,550 Views

Zydus Lifesciences has introduced Tishtha, India’s first biosimilar of Nivolumab, a pioneering immunotherapy drug for cancer treatment. Priced at ₹28,950 for 100 mg and ₹13,950 for 40 mg, the launch aims to make advanced oncology therapies more affordable and accessible to patients across India.